Investors
A MESSAGE FROM OUR CEO
”Ensuring the RA trial stays on track is key, but there are other diseases where activating the melanokortin system can potentially make a big impact.”
-
April 11, 2025 Non RegulatorySynAct Pharma Announces Initiation of Phase II Study with resomelagon (AP1189) for the Treatment of Patients with Dengue
-
April 10, 2025 RegulatorySynAct Pharma publishes Annual Report 2024
-
March 17, 2025 Non RegulatoryThe European Patent Office issues an Intention to Grant a European Patent Covering the Clinical Formulation of Resomelagon (AP1189)